Table 6.

Difference in risk of study end points among patients with AKI randomized to dual versus single renin-angiotensin system blockade

End PointCombination Therapy Patients with AKIMonotherapy Patients with AKIHazard Ratio95% Confidence IntervalP Value
Death, ESRD, or decline in eGFRa35/118 (29.7)32/71 (45.1)0.600.37 to 0.980.04
ESRD or decline in eGFRa23/118 (19.5)17/71 (23.9)0.770.47 to 1.240.28
ESRD14/128 (10.9)9/75 (12.0)0.820.34 to 1.980.66
Death15/130 (11.5)19/80 (23.8)0.450.23 to 0.880.02
  • Time-dependent analysis included AKI events occurring before reaching any component of the primary study end point adjusted for baseline eGFR and albuminuria. Data presented as number of patients with end point/number of patients at risk (%).

  • a Decline in eGFR defined as an fall in eGFR of >30 ml/min per 1.73 m2 if the eGFR was ≥60 ml/min per 1.73 m2 at randomization or a decrease in eGFR of >50% if the eGFR was <60 ml/min per 1.73 m2 at randomization.